Additionally, AAV2-delivered aromatic l-amino acid decarboxylase (AADC) gene therapy has completed phase 1/2 trial for pediatric patients with AADC deficiency (NCT02852213, NCT02926066) [33]. The gene discussed is DDC; the disease is aromatic L-amino acid decarboxylase deficiency.